CSPC Acquires China Rights to Verastem Cancer Drug in $45 Million Deal
publication date: Sep 26, 2018
CSPC Pharmaceutical in-licensed China rights to an approved cancer treatment, Copitra™, from Verastem, a Boston area biotech. Copitra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma. In the US, Copitra has been approved as a third-line treatment for several leukemia/lymphoma indications. CSPC will make a $15 million upfront payment and pay an additional $30 million in development milestones, plus sales milestones and royalties. More details....
Stock Symbols: (HK: 1093) (NSDQ: VSTM)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.